Artemis Medicare Services Limited (ARTEMISMED) Q2 FY27 Financial Results: PAT ₹31.44 & Revenue ₹287.32 Cr
| Metric | Value |
|---|---|
| Revenue | ₹287.32 Cr |
| Net Profit (PAT) | ₹31.44 |
Artemis Medicare Services Limited reported ₹287.32 crores revenue with 48.3% PAT growth to [amount context mismatch] crores and 21.5% EBITDA margin for Q1 FY27, driven by expansion of new facilities and international patient growth. ₹120 crore capex allocated to Tower IV expansion targeting 200+ beds with 23-24% margin within 2-3 years, while Raipur hospital (300-bed) launched OPD in July 2026. ₹800 crore total capex planned through FY29 including INR 55 lakh per bed cost structure, targeting 70-72% occupancy and INR 2,000 crore top-line potential from Gurgaon expansion. ₹130 crore deposit paid toward future projects separate from capex, with INR 700 crore QIP planned in 6-8 months for acquisitions and brownfield projects.
About Artemis Medicare Services Limited (ARTEMISMED)
Healthcare · Healthcare · Listed on NSE
📡 Get AI alerts when ARTEMISMED files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track ARTEMISMED — Free💡 Ask AI about this filing
📊 More ARTEMISMED filings
- 🔴 Announcement — 29 September 2026Artemis Medicare Services Ltd disclosed a GST show cause notice dated September 28, 2026 from the As...
- 🔴 Announcement — 29 September 2026Artemis Medicare Services Ltd disclosed a GST show cause notice dated September 28, 2026 from the As...
- Announcement — 28 September 2026Artemis Medicare Services Ltd announced that its trading window will close on October 1, 2026, and r...
- 🔴 Announcement — 24 September 2026Artemis Medicare Services Ltd received a credit rating reaffirmation from CARE Ratings on September ...
- 🔴 Announcement — 8 September 2026Artemis Medicare Services Ltd announced its participation in the Anand Rathi Annual Flagship Confere...
🔥 Also filed on 10 August 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when ARTEMISMED files new disclosures
Track ARTEMISMED filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ARTEMISMED — FreeFree account · 2 AI queries/day